| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H27O5S.Na |
| Molecular Weight | 330.416 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O
InChI
InChIKey=UAJTZZNRJCKXJN-UHFFFAOYSA-M
InChI=1S/C14H28O5S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-19-14(15)13-20(16,17)18;/h2-13H2,1H3,(H,16,17,18);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H27O5S |
| Molecular Weight | 307.426 |
| Charge | -1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sodium Lauryl Sulfoacetate is a safe skin friendly surfactant (foaming agent) for both skin and hair. Sodium Lauryl Sulfoacetate was used in 93 products in 1981, based on voluntary reports provided to FDA by industry; use concentrations ranged from >0.1% to >50%. In 2002 there were 68 uses (FDA 2002) and according to an industry survey in 2004 the current range of use concentrations is 0.6% to 21% (CTFA 2004). Asafety assessment on Sodium Lauryl Sulfoacetatewas published in 1987 with the conclusion “On the basis of the available data presented in this report, the Expert Panel concludes that Sodium Lauryl Sulfoacetate is safe as a cosmetic ingredient in the present practices of use and concentration” (Elder 1987). Studies available since that safety assessment was completed, along with updated information regarding uses and use concentrations, were considered by the CIR Expert Panel. After reviewing the available data, the Panel determined to not reopen this safety assessment.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
10mL of pooled blood sample was collected from 10 chickens and onefold was diluted with PBS. Peripheral blood mononuclear cells (PBMCs) were separated by density gradient centrifugation on 14mL Ficoll-paque lymphocyte separation medium at 400 g for 15 minutes and resuspended (1x10^6 cells/mL) in RPMI 1640 medium supplemented with 10% FCS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. Lymphocyte proliferation was measured using MTT method. 100 μL of the cell suspension was dispersed into each well of 96-well plates and then 62.5, 125, 250 or 500 μg/mL SLS was added (n = 12). After incubation at 39.5◦C, 5% CO2 for 44 hours, 10 μL MTT (5mg/mL) was added into each well and the incubation was continued for 4 hours. Then 100 μL of DMSO was added and incubation was continued for additional 24 hours before measurement for OD570 values using an ELISA reader (Bio-Tek Instruments, VT). The cell suspension without SLS treatment and with 5 μg/mL Con A was used as the negative and positive control, respectively.